MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41436-019-0527-9

Медицинская библиотека · Genetics in medicine : official journal of the American College of Medical Genetics · 2019

Clinical characteristics and genotypes in the ADVANCE baseline data set, a comprehensive cohort of US children and adolescents with Pompe disease.

Kishnani Priya S, Gibson James B, Gambello Michael J, Hillman Richard, Stockton David W, Kronn David, Leslie Nancy D, Pena Loren D M, Tanpaiboon Pranoot, Day John W, Wang Raymond Y, Goldstein Jennifer L, An Haack Kristina, Sparks Susan E, Zhao Yang, Hahn Si Houn, Pompe ADVANCE Study Consortium

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

PURPOSE: To characterize clinical characteristics and genotypes of patients in the ADVANCE study of 4000 L-scale alglucosidase alfa (NCT01526785), the largest prospective United States Pompe disease cohort to date.

METHODS

Patients aged ≥1 year with confirmed Pompe disease previously receiving 160 L alglucosidase alfa were eligible. GAA genotypes were determined before/at enrollment. Baseline assessments included histories/physical exams, Gross Motor Function Measure-88 (GMFM-88), pulmonary function tests, and cardiac assessments.

RESULTS

Of 113 enrollees (60 male/53 female) aged 1-18 years, 87 had infantile-onset Pompe disease (IOPD) and 26 late-onset (LOPD). One hundred eight enrollees with GAA genotypes had 215 pathogenic variants (220 including combinations): 118 missense (4 combinations), 23 splice, 35 nonsense, 34 insertions/deletions, 9 duplications (1 combination), 6 other; c.2560C>T (n = 23), c.-32-13T>G (n = 13), and c.525delT (n = 12) were most common. Four patients had previously unpublished variants, and 14/83 (17%) genotyped IOPD patients were cross-reactive immunological material-negative. All IOPD and 6/26 LOPD patients had cardiac involvement, all without c.-32-13T>G. Thirty-two (26 IOPD, 6 LOPD) were invasively ventilated. GMFM-88 total %scores (mean ± SD, median, range): overall 46.3 ± 33.0% (47.9%, 0.0-100.0%), IOPD 41.6 ± 31.64% (38.9%, 0.0-99.7%), LOPD: 61.8 ± 33.2 (70.9%, 0.0-100.0%).

CONCLUSION

ADVANCE, a uniformly assessed cohort comprising most US children and adolescents with treated Pompe disease, expands understanding of the phenotype and observed variants in the United States.

Для цитирования: Kishnani Priya S, Gibson James B, Gambello Michael J, Hillman Richard, Stockton David W, Kronn David, Leslie Nancy D, Pena Loren D M, Tanpaiboon Pranoot, Day John W, Wang Raymond Y, Goldstein Jennifer L, An Haack Kristina, Sparks Susan E, Zhao Yang, Hahn Si Houn, Pompe ADVANCE Study Consortium. Clinical characteristics and genotypes in the ADVANCE baseline data set, a comprehensive cohort of US children and adolescents with Pompe disease.. Genetics in medicine : official journal of the American College of Medical Genetics. 2019. DOI: 10.1038/s41436-019-0527-9.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.